EMA to accept biosimilar reference medicines sources outside EEA

October 1, 2012 2:04 PM

The European Medicines Agency has updated its guidance for pharmaceutical companies on biosimilar medicines to reflect the European Commission’s confirmation that it intends to accept batches of reference medicines sourced from outside the European Economic Area (EEA) in the future. This aims to facilitate the global development of biosimilars and avoid the unnecessary repetition of clinical trials.

Under the current European legal framework, companies developing a biosimilar medicine are required to identify a reference medicine that is or has been authorised in the EEA and whose batches are sourced from within the EEA. With the new approach, first announced by Commissioner John Dalli in Malta on 15 June 2012, the Agency will begin to accept reference medicine batches sourced from outside the EEA in certain pre-clinical and clinical studies in the comparability exercise.

Applicants will be responsible for establishing that batches sourced from outside the EEA are representative of the reference medicine authorised in the EEA through an extensive analytical comparison. Applicants may need to supply comparative pharmacokinetic and pharmacodynamic data to ascertain the suitability of batches of the reference medicines.

These changes will come into effect after the revision of the guideline on similar biological medicinal products. The Agency expects to release a draft version of this revised guideline for public consultation in early 2013.

The Agency has also updated its question-and-answer document on biosimilars for the public last week, in response to comments from stakeholders, including patients, healthcare professionals and the pharmaceutical industry.

The update, which was carried out in consultation with the experts from the Agency’s Biosimilar Medicinal Products Working Party (BMWP), includes more information on biological medicines in general, a statement that biosimilar medicines are not the same as generic medicines, information on the evaluation of possible differences between biosimilar medicines and their reference medicines and information on interchangeability.

NoteThe updated information for applicants can be found in question 4 of the questions and answers on similar-biological-product applications.

 

Source: EMA

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!